NCT02051218 2025-12-30Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksSwiss Cancer InstitutePhase 3 Active not recruiting1,380 enrolled
NCT07043608 2025-07-02ZAMBONIUniversity of California, San FranciscoPhase 2 Not yet recruiting20 enrolled